Kelowna, British Columbia--(Newsfile Corp. - May 17, 2024) - Tryp Therapeutics, Inc. (CSE: TRYP) ("Tryp" or the "Company") announces, that it has filed amended financial statements for the six months ended...
Monday U.S. Economic Lookahead NAHB Home Builders Index (Dec.) Featured Earnings HEICO ...
The psychedelic story is coming back strong. All after Sen. Cory Booker tweeted, “Massive breakthroughs in medical studies with psilocybin and MDMA are showing strong promise for patients with PTSD,...
Today announced the filing of two new provisional patent applications. One patent application, #63/405,786, ...
/CNW/ -- Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) ("Tryp" or the "Company"), a clinical-stage biotechnology company focused on developing psilocybin-based...
Announced a non-brokered private placement to its co-Founder and Executive Director, William J. Garner, ...
Announced today that it has received confirmation from the U.S. Food and Drug Administration that its ...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) just announced that it would be proceeding with its upcoming Phase 2a fibromyalgia study, following a confirmation from the U.S. Food and Drug Administration...
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) Â is advancing toward the launch of four phase 2a studies of its two novel drug candidates, TRP-8802 and TRP-8803, for treating fibromyalgia, phantom limb pain,...
Atai Life Sciences (NASDAQ: ATAI) , a clinical-stage biopharmaceutical company whose objective is to transform how mental health conditions are treated, has increased its stake in Compass Pathways. Compass...